MannKind Corp Total Liabilities
MannKind Corp total liabilities. Based on the latest financial reports, MannKind Corp (MNKD) has total liabilities worth $799.50 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MannKind Corp liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of MannKind Corp (2000–2025)
Total liabilities of MannKind Corp from 2000 to 2025. This chart illustrates how MannKind Corp's total liabilities have evolved over time, based on quarterly financial data. Explore MNKD long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
MannKind Corp Competitors by Total Liabilities
The table below lists competitors of MannKind Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Jufei Optoelectronics
SHE:300303
|
China | CN¥2.53 Billion |
|
UTI Asset Management Company Limited
NSE:UTIAMC
|
India | Rs-45.05 Billion |
|
TMC the metals company Inc
NASDAQ:TMC
|
USA | $215.07 Million |
|
Aker Biomarine AS
OL:AKBM
|
Norway | Nkr237.50 Million |
|
Certara Inc
NASDAQ:CERT
|
USA | $493.79 Million |
|
Cymbria Corporation
TO:CYB
|
Canada | CA$138.94 Million |
|
PROS Holdings Inc
NYSE:PRO
|
USA | $521.11 Million |
|
Hagar hf
IC:HAGA
|
Iceland | Ikr77.41 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down MannKind Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see MNKD total asset value.
Liquidity & Leverage Metrics
MannKind Corp Total Liabilities Ratios Explained
MannKind Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -11.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MannKind Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MannKind Corp (2000–2025)
The table below shows the annual total liabilities of MannKind Corp from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $843.20 Million | +78.40% |
| 2024-12-31 | $472.66 Million | -34.48% |
| 2023-12-31 | $721.37 Million | +32.16% |
| 2022-12-31 | $545.82 Million | +2.89% |
| 2021-12-31 | $530.51 Million | +83.55% |
| 2020-12-31 | $289.03 Million | +1.68% |
| 2019-12-31 | $284.25 Million | +0.52% |
| 2018-12-31 | $282.79 Million | -5.52% |
| 2017-12-31 | $299.31 Million | +2.98% |
| 2016-12-31 | $290.66 Million | -39.03% |
| 2015-12-31 | $476.75 Million | +1.82% |
| 2014-12-31 | $468.21 Million | +61.81% |
| 2013-12-31 | $289.36 Million | -20.07% |
| 2012-12-31 | $361.99 Million | -29.46% |
| 2011-12-31 | $513.21 Million | +10.89% |
| 2010-12-31 | $462.79 Million | +50.93% |
| 2009-12-31 | $306.62 Million | +56.66% |
| 2008-12-31 | $195.72 Million | +9.13% |
| 2007-12-31 | $179.34 Million | +14.78% |
| 2006-12-31 | $156.25 Million | +630.34% |
| 2005-12-31 | $21.39 Million | +63.06% |
| 2004-12-31 | $13.12 Million | -8.25% |
| 2003-12-31 | $14.30 Million | +2.14% |
| 2002-12-31 | $14.00 Million | +30.17% |
| 2000-12-31 | $10.76 Million | -- |
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more